Does Wegovy Increase Liver Enzymes — and Should You Be Concerned?

What the trial data say about semaglutide and liver enzymes

The most direct evidence comes from the STEP programme. In the STEP 1 trial published in the New England Journal of Medicine, adults with obesity who received semaglutide 2.4 mg weekly for 68 weeks saw meaningful reductions in body weight (roughly 15% on average) alongside improvements in several metabolic markers, including liver-related ones. Elevated alanine aminotransferase (ALT) and aspartate aminotransferase (AST), the two enzymes most commonly checked to assess liver stress, fell rather than rose in the majority of participants who had elevated baseline levels.

This trajectory makes biological sense. Excess adipose tissue, particularly visceral fat around the abdomen, drives the chronic low-grade inflammation that pushes liver enzymes up in the first place. As weight falls and fatty deposits in the liver reduce, enzyme levels tend to follow. That is partly why the MHRA granted a conditional approval in July 2026 for Wegovy to treat MASH (metabolic dysfunction-associated steatohepatitis) in adults with moderate-to-advanced liver fibrosis. That regulatory decision reflects the evidence base rather than contradicting it.

None of this means liver enzyme changes are impossible. Rapid weight loss of any cause (including that produced by GLP-1 medicines) can occasionally prompt a transient rise in liver enzymes as fat is mobilised quickly from hepatic tissue. This effect is typically short-lived and resolves as weight stabilises.

When liver enzyme changes during Wegovy treatment deserve closer attention

Most enzyme fluctuations spotted on routine bloods during Wegovy treatment are mild and self-limiting. The picture that warrants quicker action is a persistent or pronounced rise, particularly if it coincides with symptoms. Jaundice (yellowing of the skin or whites of the eyes), dark urine, pale stools, or sustained tenderness in the upper-right abdomen are all reasons to contact your GP or prescriber without waiting for a scheduled review.

Gallbladder problems are a recognised side effect of GLP-1 receptor agonists. The NHS medicines guidance on semaglutide notes that gallstones and gallbladder inflammation (cholecystitis) can occur, and these can cause liver enzyme elevations secondary to biliary obstruction. It is worth knowing that symptom (right-sided or central upper abdominal pain, sometimes spreading to the shoulder) so you can describe it clearly if it arises.

People with pre-existing liver conditions, including cirrhosis or active hepatitis, should discuss treatment suitability carefully with a specialist before starting. The prescriber reviewing your Wegovy consultation will ask about liver history; that question is not bureaucratic, it shapes the decision. If your liver function tests are being monitored regularly for an unrelated reason, tell your prescriber so they can interpret any trend in context.

The new MASH indication, what it means for people with fatty liver disease

The July 2026 approval for MASH is significant, though it sits within a specialist clinical setting rather than general weight-management prescribing. People with MASH and moderate-to-advanced fibrosis are a distinct group from most people seeking Wegovy for weight loss, and treatment in that context would be overseen by a hepatologist or gastroenterologist, not a community prescriber.

For people who have been told they have non-alcoholic fatty liver disease (NAFLD) (now often called metabolic dysfunction-associated steatotic liver disease, or MASLD) but do not have advanced fibrosis, the position is different. Weight loss itself is the primary treatment recommended by hepatology guidelines, and Wegovy's efficacy in achieving sustained weight reduction makes it a reasonable candidate for discussion with your GP or liver specialist. Whether it is suitable for you specifically is a clinical decision that requires knowing your current enzyme levels, imaging findings and overall health picture.

If you are curious about how the dose schedule works or how titration is managed over time, that context can help you understand why incremental steps matter for tolerability, including liver tolerability. Many people also wonder whether increasing the Wegovy dose actually leads to greater weight loss, which is a reasonable question when thinking about how the escalation schedule affects both outcomes and tolerability.

Talking to a prescriber about your liver health before starting

Starting Wegovy when you have any liver history is exactly the kind of situation where a thorough clinical conversation matters most. A prescriber will want to know about any existing liver diagnoses, current medications that are themselves hepatotoxic, and whether your enzyme levels are already above the normal range. Some people keep their semaglutide pen in the fridge door and take a weekly dose without any further thought, but getting there safely means having those baseline questions answered first.

The NICE appraisal of semaglutide for weight management (TA875) sets out the clinical framework within which this medicine is recommended, and liver health is part of the broader assessment a clinician performs before and during treatment. At nume, every consultation is read by a GPhC-registered Independent Prescriber, a real clinician who considers your full health picture before any prescription is issued. You can check your eligibility through a free consultation, and our prescribers are available for aftercare seven days a week if questions arise once you are on treatment.

For a broader look at how dose increases are managed, including when and how the Wegovy dose is typically increased throughout treatment, the information is there to help you prepare a more informed conversation with your clinical team. Some people also ask about less obvious changes they notice on treatment, such as whether Wegovy has any effect on libido, and understanding the full picture of how the medicine works can help frame those conversations with your prescriber. Our clinical team page sets out who reviews consultations at nume.